Prevalence of oral glucocorticoid usage in the United States: A general population perspective

Arthritis Care and Research

Volumn 65, Issue 2, 2013, Pages 294-298

  Overman, Robert A ^a   Yeh, Jun Yen ^b   Deal, Chad L ^b  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTISONE; DEXAMETHASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PARATHYROID HORMONE[1-34]; PREDNISOLONE; PREDNISONE; VITAMIN D;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; TREATMENT DURATION; UNITED STATES;

EID: 84873206093     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21796     Document Type: Article

References (15)

1. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893-9.
2. Van Staa TP, Leufkens HG, Cooper C,. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis Int 2002; 13: 777-87.
3. Braithwaite RS, Col NF, Wong JB,. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003; 51: 364-70.
4. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496-503.
5. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-26.
6. Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005; 52: 2485-94.
7. Feldstein AC, Elmer PJ, Nichols GA, Herson M,. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005; 16: 2168-74.
8. Walsh LJ, Wong CA, Pringle M, Tattersfield AE,. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996; 313: 344-6.
9. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C,. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 105-11.
10. Gudbjornsson B, Juliusson UI, Gudjonsson FV,. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002; 61: 32-6.
11. Fardet L, Petersen I, Nazareth I,. Description of oral glucocorticoid prescriptions in general population. Rev Med Interne 2011; 32: 594-9. In French.
12. United States Department of Health and Human Services, Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. 2011. URL: http://www.cdc.gov/nchs/nhanes.htm.
13. Paulose-Ram R, Hirsch R, Dillon C, Gu Q,. Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among U.S. adults. Pharmacoepidemiol Drug Saf 2005; 14: 257-66.
14. United States Department of Health and Human Services, Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: questionnaires, datasets, and related documentation. 1999 -2008. URL: http://www.cdc.gov/nchs/nhanes/nhanes-questionnaires.htm.
15. United States Department of Health and Human Services, Centers for Disease Control and Prevention. NHANES response rates and CPS totals. 2011. URL: http://www.cdc.gov/nchs/nhanes/response-rates-cps.htm.